Sanofi to End Nurix’s SAR448272 Program After Phase 1 Trial
Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial and terminate the program, ending potential payments tied to it.
Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial and terminate the program, ending potential payments tied to it.